Deksatobropt drops Ch. 5ml vial-cap.

$6.26

Deksatobropt drops Ch. 5ml vial-cap.

Quantity:

SKU: 1271798892 Categories: , , Tags: ,

Description

Composition
Active substance:
1 ml contains: Dexamethasone – 1.0 mg; tobramycin – 3.0 mg.
Excipients:
Tyloxapol – 0.5 mg; Hypromellose (HPMC 4000 cP) – 5,0 mg; sodium sulfate – 12.0 mg; sodium chloride – 3.3 mg; disodium edetate dihydrate – 0.10 mg; Benzalkonium chloride – 0.10 mg; 1M sodium hydroxide solution or 1 M sulfuric acid solution -up to pH 5.0 – 6.0; Purified water – up to 1 ml.
Description:
The suspension white or nearly white, possible presence of sediment, which quickly dissipated with gentle shaking.
Product form:
Eye drops. 5 ml of the drug in the polymeric white-dropper bottle closed with a polymeric cap with a safety ring. In one flakonu- drip chamber together with instructions for use in a cardboard box.
Contraindications
– viral diseases of the eye (including keratitis caused by Herpes simplex, chickenpox); – Mycobacterial infections of the eye; – fungal diseases of the eye; – Children up to age 18; – Hypersensitivity to any component of the formulation. – state after removal of a foreign body from the cornea.
Indications
Infectious diseases of the eye, including blepharitis, conjunctivitis, Blepharoconjunctivitis; keratitis (without epithelial injury); prevention and treatment of inflammatory events in the postoperative period after cataract extraction.
Interaction with other drugs
Drug interaction preparation DeksaTobropt not established. In case of using with other topical ophthalmic preparations, the interval between their application should be at least 5 minutes.
Overdose
To the present cases of drug overdose DeksaTobropt were reported.
pharmachologic effect
Pharmacological group:
Glucocorticosteroids for local use + aminoglycoside antibiotic.
Pharmacodynamics:
DeksaTobropt – combined formulation with an antibacterial and antiinflammatory action for local application in ophthalmology. Tobramycin antibiotic with a wide spectrum of the action of the amine groups of communication glyco d s. Active Ocean rel g ramps ol ozhitelny x and Gram-negative microorganisms: Staphylococcus spp. (Including Staphylococcus aureus, Staphylococcus epidermidis / including strains resistant to penicillin); Streptococcus spp. (Including some beta-hemolytic group A types, some types of non-hemolytic and some strains of Streptococcus pneumoniae), Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most of the species Proteus vulgaris, Haemophilus influenzae, Haemophilus aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus (Herellea vaginacola), as well as some types of Neisseria spp.
Dexamethasone – glucocorticosteroid (GCS). It has a pronounced anti-inflammatory, anti-allergic and antiinflammatory action. Dexamethasone actively suppress inflammation by inhibiting release of inflammatory mediators by eosinophils, mast cells and migration of reducing capillary permeability. Not mineralocorticoid activity.
Pharmacokinetics:
After topical administration, tobramycin is absorbed through the cornea and conjunctiva. A very small amount reaches the aqueous humor. Tobramycin reaches the systemic circulation at very low concentrations. When applied topically, systemic absorption of dexamethasone – low. After instillation into the eye, good penetration into the epithelium of cornea and conjunctiva, eye aqueous humor. Maximum activity is achieved within 10-20 minutes after drug application. Distribution of the drug was observed in the blood plasma, bile, the liver, kidneys and renal excretion after 30 minutes from the time of reception.
Pregnancy and breast-feeding
Sufficient experience of use of the drug during pregnancy, breast-feeding is not. Application DeksaTobropta during pregnancy only if the expected benefits of therapy to the mother outweighs the potential risk to the fetus. At the time of treatment should stop breastfeeding.
Conditions of supply of pharmacies
By prescription.
side effects
– local allergic reaction: swelling, itchy eyelids, redness of the conjunctiva; – an increase in intraocular pressure (with prolonged use); – if used consistently, for more than 3 months, may develop corneal fungal infections; – deceleration regeneration; – posterior subcapsular cataracts, secondary infection; – headache, increased blood pressure.
special instructions
DeksaTobropt is intended for topical use (not used for injection). When applying formulations containing glucocorticosteroids, more than 10 days must regularly measure intraocular pressure. When assigning DeksaTobropt drug simultaneously with the antibiotic aminoglycoside for systemic use, it is necessary to control the concentration of tobramycin in serum, which should not exceed 8 mg / ml. With the development of allergic reactions, use of the drug should be discontinued.
Use in Pediatrics
At the moment, the safety and efficacy of the drug in children have not been established.
Effects on ability to drive vehicles engaging in other activities that require concentration and speed of psychomotor reactions.
On the adverse effects of the drug on the ability to drive and doing other activities that require concentration and speed of psychomotor reactions, have been reported. However, given that the patient after the application temporarily lost clarity of vision is not recommended to drive vehicles or operate complex machinery immediately after instillation of the drug. Since eye drops contain benzalkonium chloride as a preservative, it can lead to irritation, and it is also known that the preservative can discolor soft contact lenses. Therefore, before using the product DeksaTobropt patients must remove contact lenses and should be informed that you must wait 15 minutes after instillation DeksaTobropt medication before inserting contact lenses.
Storage conditions
In dry the dark place at a temperature not exceeding 25 C. After opening the vial should be stored at a temperature not higher than 25 ° C and used within 4 weeks. Keep out of the reach of children.
Dosing and Administration
Locally. The drug instilled 1-2 drops into the conjunctival sac of the affected eye (or eyes) every 4-6 hours. After cataract surgery dose can be increased up to one or two drops every two hours for 24 hours. The frequency of the drug should gradually decrease with the improvement of clinical signs. It is not necessary to reduce the dose in elderly patients. Before using, the vial should be shaken. The bottle must be closed after each use. Do not touch the pipette tip to the eye to maintain sterility of the solution.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

Rompharm

There are no reviews yet.

Add your review